Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Occidental Petroleum (OXY): Energy stocks gained modestly ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Novo Nordisk announced it will stop collaborating with Hims & Hers Health regarding the distribution of Wegovy weight loss ...

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...